

25 **Abstract**

26

27 In Cameroon, recent studies have documented several cases of dengue infection in some urban
28 areas, but dengue-malaria coinfection malaria was little investigated, especially in the East
29 region. From the 6th July to the 4th September 2020, a case-control study including 50 cases
30 (malaria-positive subjects) and 90 controls (non-malaria subjects) was carried out at the Bertoua
31 Regional Hospital. Participants were prospectively enrolled and administered with a
32 questionnaire to record information such as age, sex, dwelling place, dengue knowledge, and
33 the environment's quality. Blood specimens were then collected and screened for dengue
34 infection using the NS1/IgG/IgM rapid diagnostic tests and hematological parameters were
35 measured using a MINDRAY-type hemacytometer. Of the malaria patients, 14% (7/50) were
36 tested positive for dengue fever against 66.66% for the controls (60/90). Most malaria patients
37 had a secondary dengue infection (57.14%, 4/7) while most of the non-malaria patients faced a
38 primary infection (61.66%, 37/60). In both groups, women were more exposed than men to
39 dengue and there was a significant association between the dwelling place and dengue
40 seropositivity. Moreover, young subjects <16 years old were significantly more associated with
41 dengue than 16-30 years old (OR=16.24, P=0.042 for cases vs, OR=21, P=0.0001 for controls).
42 The analysis of hematological parameters showed a significant decrease (P<0.001) in platelets
43 in cases compared to control. These results suggest that dengue fever targets malaria- than non-
44 malaria patients with different serological characteristics in Bertoua city. However, co-infected
45 patients demonstrated a greater clinical vulnerability than monoinfected patients, urging the
46 need for epidemiological surveillance.

47 Key words : dengue infection, Case-control study, Bertoua, Malaria

48

49

50 **Introduction**

51 Dengue is the most widespread mosquito-borne viral disease throughout the world in
52 particular in tropical areas [1]. According to WHO, the number of dengue cases reported over
53 the last decades grew from 505,430 cases in 2000 to 5.2 million in 2019 worldwide [2]. Some
54 predictions state that 2.25 (1.27–2.80) billion more people will be exposed to dengue from here
55 to 2080 leading the whole population at risk to over 6.1 billion [3]. In Africa, previous studies
56 have documented numerous dengue cases, some of them causing severe epidemics [4,5].
57 Moreover, dengue fever is endemic in several countries and frequently associated with the
58 etiology of febrile illnesses interfering thereby with certain infectious diseases like malaria.
59 Indeed, both infections are clinically difficult to differentiate as they display similar symptoms
60 [6].

61 Dengue is caused by the Dengue virus (DENV), a single-stranded positive RNA virus,
62 member of the Flaviviridae family which presently exists under four serotypes (DENV1-4)
63 having each distinct antigenic and genetic features [7]. These serotypes are able to induce two
64 types of dengue namely classic dengue characterized by symptoms such as retroorbital pain,
65 headache, severe myalgias, and severe hemorrhagic dengue fever which causes more serious
66 complications resulting in bleeding and death [1]. DENV is mainly carried and spread to
67 humans by *Aedes* mosquitoes [8]. Recent evidence suggests that human-driven changes
68 including deforestation, urbanization ineffective vector control, and climate change would have
69 greatly promoted the expansion of this infection to the African continent. [3].

70 In Cameroon, several studies have reported the presence of dengue infection in urban and
71 rural areas [9–16]. Different dengue serotypes were also characterized in especially DENV-1,
72 DENV-2, and DENV-3 serotypes in asymptomatic [17] and febrile patients [9,14]. Dengue-
73 malaria coinfection was firstly documented in children attending health centers in Yaoundé
74 [15]. Later, Nkengfou et al found a coinfection rate of 19.5% in infants consulting at the Centre

75 Mère-Enfant in Yaounde [10]. In another study, a malaria-dengue coinfection rate of 13% was
76 documented in the New-Bell district in Douala [14]. More recently, we reported a
77 seroprevalence of 8.95% in a cohort of patients surveyed in the Ngaoundere Regional Hospital
78 in the Adamawa region [18]. However, in the East region of Cameroon, there are currently no
79 data on DENV circulation, to the best of our knowledge. Nevertheless, previous reports gave
80 evidence of the invasion of this region by *Aedes aegypti* and *Aedes albopictus* [19,20] as in
81 other towns such as Douala and Yaounde where dengue infection has been identified.
82 Moreover, several cases of severe malaria have been documented in this region [21]. According
83 to Antonio-Kondjo et al. the East region is a reservoir for malaria transmission in Cameroon
84 and is considered by the Ministry of Health as one of the most affected areas by malaria [22].
85 Therefore, concurrent dengue and malaria infections are not to be excluded in people living in
86 this area. The aim of this work was to bring data on dengue presence in the Bertoua city and to
87 perform a compared analysis of this infection between malaria and non-malaria patients.

88

89 **Materials and Methods**

90 **Study site**

91 This cross-sectional and descriptive study was conducted from 6th July to the 4th September
92 2020 at the Bertoua Regional Hospital (BRH) (Fig 1).

93

94 **Fig 1 : Geographical map showing the location of the Bertoua Regional Hospital**

95

96 Bertoua is the capital of the Department of Lom and Djerem and the regional capital of the East,
97 the largest forest region in Cameroon. It is located 350 km from yaoundé with the following
98 geographical coordinates 4 ° 34 ' 30 " north, 13 ° 41 ' 04 " east. It covers 100 km² with around

99 a whole population estimated to 281139 inhabitants [23]. Its climate is subtropical with three
100 seasons including a large dry season which begins in December and ends in mid-March; a small
101 rainy season which goes from mid-March to mid-May, a big rainy season which goes from mid-
102 September to November. The temperature is high (average between 23-25 ° C) with a peak
103 around 30°C. The average oscillates between 23 and 25 °C [24]. Precipitation is relatively
104 abundant there (1,500 to 2,000 mm of rainfall per year).

105

106 **Ethical Considerations**

107 This study protocol was approved by the National Ethics Committee for Research on Human
108 Health (CNRESH) (Ethical Clearance No. 2020/01/58/ CE/CNERSH/SP). Permission for
109 sample collection at BRH was granted by the Regional Delegate for Public Health of the East
110 region (Authorization N°622/L/MINSANTE/SG/DRSPE/BFP). The risks and benefits of the
111 study were explained to each participant, afterwards, a written and signed consent form was
112 obtained from each voluntary subject. Assents and consents for young participants less than 21
113 years old were given by their parents or legal guardians.

114

115 **Study population and inclusion criteria**

116 Have been included in the study, volunteer patients aged between 0-50 years old, and consulting
117 at the BRH. Patients presenting at least two of the following symptoms: headache, asthenia,
118 myalgia, rash, arthralgia, nausea, abdominal pain, vomiting, and loss of appetite and screened
119 positive for malaria infection were recruited as the case group (n=50) while those screened
120 negative for malaria with no evidence of the above-mentioned symptoms were included in the
121 control groups (n=90). All patients were administered a standardized questionnaire to collect
122 socio-demographic data as well as the sex, age, dwelling place, dengue knowledge, and the

123 environment's quality. Were excluded, patients under malaria treatment, with
124 immunodeficiencies or sexually transmitted diseases.

125

126 **Laboratory tests**

127 **Malaria parasite detection**

128 Malaria screening was carried out using a whole blood thick smear as previously described
129 [25]. Briefly, a drop of freshly collected blood was placed on a degreased slide, then the latter
130 was spread regularly using a vaccinostyle for 2 min. The slide was then inverted and then dried
131 flat on a support for 1 hour at room temperature. The thick drop was then covered abundantly
132 with 3 drops of a 10% Giemsa solution and 2 ml of neutral water. The whole was incubated for
133 5-10 minutes until completely discolored and then fixed with methyl alcohol. The excess liquid
134 was poured carefully and replaced again with the Giemsa and neutral water mixture for 20 min
135 of incubation. The slide was washed gently with distilled water and then air dried. The thick
136 drop was observed under a microscope at 100x magnification using oil immersion.

137

138 **Dengue diagnosis tests**

139 Dengue screening was carried out using the NS1/IgG/IgM combined diagnostic kit provided by
140 Medsinglong Global Group Co., Limited (Guangzhou, China). It is a one-step rapid test based
141 on the principle of immunochromatography with double-antibody sandwich immunoassay and
142 capture made of two devices: the NS1 antigen test (on the left side) and the IgG/IgM test (at the
143 right side). After adding the sample to the test device, the specimen is absorbed and mixed with
144 the antibody/antigen conjugates. Then, it flows across the pre-coated membrane. When the NS1
145 antigen levels in the sample are above the detection limit of the test, they combined to the

146 antibody conjugate and then are fixed by the anti-NS1 antibody immobilized in the test region
147 (T) of the device giving a colored band in T which shows a positive result. Regarding the
148 IgG/IgM test, when the dengue-specific antibodies in the specimen are at/above the limit of
149 detection, they bind to the antigen conjugate in the conjugate pad and then are caught by the
150 anti-human IgG or anti-human IgM immobilized in the test region (T1 and T2) of the device
151 giving therefore a positive result in these regions. All tests were carried out following the
152 manufacturer's instructions. For the NS1 test, three drops of the blood sample (60-80µl) were
153 added in the appropriate well in the cassette device using a dropper, while 10µl of the plasma
154 sample were added in well A followed by 2 drops of the dilution buffer in the B well for the
155 IgG/IgM test. The cassette was let at room temperature for 20 min and the results were
156 interpreted following the manufacturers instructions.

157 As stated previously [18], the performances of this kit were compared with the Australian
158 Panbio dengue test kit. A sensitivity of 92.22% (166/180) and 97.30% (180/185) were reported
159 with the NS1 antigen and IgG/IgM antibody respectively, while specificity of 100% (170/170)
160 was observed with the NS1 antigen and 98.18% (162/165) with the antibodies. Similarly, no
161 cross-reactivity was found with the chikungunya, measles, rubella, typhoid fever, leptospirosis,
162 influenza, hemorrhagic fever with renal syndrome, septicemia, tsutsugamushi disease, hepatitis
163 B and C, HIV, malaria *P. falciparum*, *P. vivax*, and epidemic cerebrospinal meningitis.

164

165 **Measurement of hematological parameters**

166 The haematological parameters of the study participants were determined using a MINDRAY
167 brand automated hemacytometer. Its principle was based on the counting of the Figd elements
168 of the blood in an automatic way and the measurement of their proportion in the plasma liquid.
169 To perform this test, 5 mL of blood was drawn using a syringe and placed in a tube containing
170 the anticoagulant ethylene diamine tetra acetate (EDTA). The tube was shaken, then placed in

171 the hemacytometer which aspirated 2 mL of this blood. A few minutes after this device
172 displayed the result. The following parameters were evaluated: the number of erythrocytes,
173 leukocytes, platelets, hematocrit, lymphocytes, neutrophils and mean blood volume.

174

175 **Statistical analysis**

176 Data collected were processed in excel spreadsheets. Statistical analyzes were conducted using
177 the Graphpad Prism 5.0 software (San Diego, USA). Data were displayed as mean plus or minus
178 standard error to mean, and percentages. Mean comparisons were performed using the two-
179 way analysis of variance followed by a Bonferonni posttest. The χ^2 test was used to determinate
180 associations between dengue seropositivity, and the socio-demographic characteristics and the
181 odds ratios (OR) were calculated The significant difference was declared for $P < 0.05$.

182

183 **Results**

184 **General characteristics of the study population**

185 The general characteristics of the study population are displayed in Table 1. As shown by this
186 table, women (60%) were more represented than men (40%) in both case and control groups.
187 The mean age of the case group was 25.5 years old while that of the control was 23.83 years
188 old. In cases groups, subjects from 31-50 years were the most represented (40%) while in the
189 control groups, age ranges were balanced enough (33.33%). In the case groups, most
190 participants originated from Ngaikaida (20%) and Monou (14%) neighborhoods while in the
191 controls, they were issued from Tindamba (16.66%) and Ngaikaida (14%). In both groups, a
192 huge majority of the participants reported to live in a risky environment (94% for cases vs 100%

193 for controls) for dengue infection and were not aware of what dengue infection was about
194 (>96%).

195 **Table 1.** General characteristics of the study population

		Cases	Controls
Gender	Male	20 (40%)	36 (40%)
	Female	30 (60%)	54 (60%)
	Total	50	90
Age range (years)	[0-15]	15 (30%)	30 (33.33%)
	[16-30]	15 (30%)	30 (33.33%)
	[31-50]	20 (40%)	30 (33.34%)
	Total	50	90
Mean age (years)		25.5	23.83
Dwelling place	Enia	5 (10%)	7 (7.77%)
	Tigaza	5 (10%)	10 (11.11%)
	Ngaikaida	10 (20%)	13(14.44%)
	Yademe	5 (10%)	9 (10%)
	Mokolo	2 (4%)	5 (5.55%)
	Tindamba	6 (12%)	15 (16.66%)
	Italy	5 (10%)	11 (12.25%)
	Monou	7 (14%)	10 (11.11%)
	Kano	5 (10%)	10 (11.11%)
	Total	50	90
Dengue knowledge	Yes	2 (4%)	3 (3.33%)
	No	48 (96%)	87(96.67%)
	Total	50	90
Risky environment	Yes	47 (94%)	90 (100%)
	No	3 (6%)	0
	Total	50	90

196

197 **Dengue seroprevalence data in case and control groups**

198 Data from Table 2 summarize the overall seroprevalence of dengue in both case and control
199 groups as well as the type of serology detected in these patients. According to this table, the
200 seroprevalence of dengue was lower (14%, 4/7) in malaria patients than in non-malaria patients
201 (66.66%, 60/90). Patients from the case group were mostly found to have a secondary dengue
202 infection (57.14%) than primary dengue infection (42.86%). The secondary dengue infection
203 was marked by the concurrent presence of a NS1/IgM/IgG or IgM/IgG serology while primary
204 infection was confirmed by the solely detection of IgM antibodies. Regarding the controls,
205 primary dengue (61.66%) was more frequent than secondary dengue infection (38.34%).
206 Patients with primary infection had a NS1 or NS1/IgM serology while those with secondary
207 dengue infection had mostly IgM/IgG serology.

208 **Table 2.** Typology of dengue seropositivity in case and control groups

	Cases N=50	Controls N=90
Dengue seropositivity rate	7/50 (14%)	60/90 (66.66%)
Primary dengue infection		
NS1	-	28
IgM	3	-
NS1/IgM	-	9
Total	3/7 (42.86%)	37/60 (61.66%)
Secondary dengue infection		
IgM/IgG	2	15
NS1/IgM/IgG	2	8
Total	4/7 (57.14%)	23/60 (38.34%)

209

210

211 **Effect of the socio-demographic parameters on DENV**

212 **seropositivity**

213 In order to identify the risk factors that might increase susceptibility to dengue infection in both
 214 malaria and non-malaria patients, the statistical association between age, gender, the dwelling
 215 place, the knowledge of dengue and the living in a risky environment with dengue seropositivity
 216 has been tested using the chi-square test. The results are presented in Tables 3 and 4 (Bold
 217 values in the P-value column are significant values at $P < 0.05$ using the Chi-square test). As
 218 shown by these tables, no statistical association was found between dengue seropositivity and
 219 the gender, dengue knowledge, or the fact of living in a risky environment both in malaria and
 220 non-malaria patients. However, for both groups, age and the dwelling place were significantly
 221 correlated to dengue seroprevalence. As far as case group is concerned, young subjects (0-15
 222 years old) were found to be highly susceptible to dengue compared to those of 16-30 years old
 223 (OR: 16.24; $P = 0.042$), while some neighborhoods like Enia, Tigaza, Ngaikaida, Yademe and
 224 Italy were more risky for dengue infection ($P < 0.05$) (Table 3). Regarding the control group,
 225 children < 16 years old were also found to be highly exposed (OR: 21, $P = 0.0001$) to dengue
 226 compared to older ones. However, only Enia, Monou and Kano were identified as risky quarters
 227 for dengue infection (Table 4).

228 **Table 3.** Statistical association between dengue seropositivity and socio-demographical factors
 229 in case group

Variables	Dengue + Malaria +	Dengue – Malaria +	Odds ratio (OR)	OR (CI 95%)	P-value
Gender	Male	2(28.6%)	18(41.8%)	0.55	0.10-3.22
	Female	5(71.4%)	25(58.2%)		
	Total	7 (100%)	43 (100%)		

Age range (years)	[0-15]	5(71.4%)	10(23.2%)	16.24	0.80-326.1	0.042
	[16-30]	/	15(34.9%)	1		
	[31-50]	2(28.6%)	18(41.9%)	4.18	0.18-94	0.495
	Total	7(100%)	43(100%)			
Dwelling Place	Enia	/	5(11.6%)	0	0.00-0.60	0.02
	Tigaza	/	5(11.6%)	0	0.00-0.60	0.02
	Ngaikaida	1(14.3%)	9(20.9%)	0.04	0.003-0.587	0.03
	Yademe	/	5(11.6%)	0	0.00-0.60	0.02
	Mokolo	/	2(4.7%)	0.00	0.00-1.53	0.16
	Tindamba	1(14.3%)	5(11.6%)	0.08	0.005-1.316	0.10
	Italy	/	5(11.6%)	0	0.00-0.60	0.02
	Monou	5(71.4%)	2(4.7%)	1		
	Kano	/	5(11.6%)	0	0.00-0.60	0.02
	Total	7(100%)	43(100%)			
Dengue knowledge	Yes	00	2(4.7%)			
	No	7(100%)	41(95.3%)	0.0	0.0-13.77	0.99
	Total	7(100%)	43(100%)			
Risky environment	Yes	7(100%)	40(93%)	0.0	0.00-7.42	0.99
	No	00	3(7%)			
	Total	7(100%)	43(100)			

230

231 **Table 4.** Statistical association between dengue seropositivity and socio-demographical factors

232 in control group

Variables		Dengue + Malaria -	Dengue – Malaria -	Odds ratio (OR)	OR (CI 95%)	P-value
Gender	Male	25(41.7%)	11(36.7%)	1.23	0.5-3.04	0.81
	Female	35(58.3%)	19(63.3%)			
	Total	60(100)	30(100%)			
Age range (years)	[0-15]	28(46,7%)	2(6,7%)	21	4.19-105.1	0.0001
	[16-30]	12(20%)	18(60%)	1		

	[31-50]	20(33,3%)	10(33,3%)	3	1.046-8.605	0.069
	Total	60(100%)	30(100%)			
Dwelling Place	Enia	7(11.7%)	/	/18.33	0.80-416	0.033
	Tigaza	3(5%)	7(23.3%)	0.53	0.081-3.5	0.65
	Ngaikaida	10(16.7%)	3(10%)	4.167	0.66-26.30	0.187
	Yademe	4(6.7%)	5(16.7%)	1		
	Mokolo	/	5(16.7%)	0.111	0.0047-2.59	0.22
	Tindamba	10(16.7%)	5(16.7%)	0.83	0.178-	1
	Italy	6(10%)	5(16.7%)	1.5	0.25-8.82	1
	Monou	10(16.7%)	/	25.67	1.15-59	0.018
	Kano	10(16.7%)	/	25.67	1.15-59	0.018
	Total	60(100%)	30(100%)			
Dengue knowledge	Yes	2(3.3%)	1(0.3%)	1	0.08-11.50	1
	No	58(96.7%)	29(96.7)			
	Total	60(100%)	30(100%)			
Risky environment	Yes	60(100%)	30(100%)			
	No	00	00			
	Total	60(100%)	30(100%)			

233

234 **Compared analysis of the hematological parameters of case and** 235 **control groups**

236 In order to gauge the influence of dengue-malaria coinfection on clinical status of patients, a
 237 compared analysis of the hematological parameters has been performed between the case and
 238 control groups. In general, co-infected subjects were found to have higher than normal levels
 239 of white blood cells ($15.22 * 10^9$ cells /L $> 4-10 * 10^9$ cells/L), lymphocytes ($9.66 * 10^9$ cells /L
 240 $> 0.6-4.1 * 10^9$ cells/L), and neutrophils, ($13.44 * 10^9$ /L $> 2-7.8 * 10^9$ / L respectively).
 241 Likewise, these subjects displayed lower than normal values of red blood cells ($2.05 * 10^9$ / L
 242 $< 3.5 * 10^9$ / L), platelets ($78.89 * 10^9$ / L $< 100 * 10^9$ / L), hematocrit (29% $< 36%$) and red blood

243 cell volume (74 g/dL <80 g/dL). For dengue mono-infected patients, higher than normal values
244 were recorded for the number of white blood cells (11.89×10^9 cells/ L), lymphocytes (8.55×10^9
245 / L) and neutrophils (13.89×10^9 / L) as well as a slight decrease of the hematocrit rate (35.56%).
246 However, red blood cells numbers, number of platelets and the mean blood volume were
247 relatively normal. A compared analysis of these hematological parameters revealed a significant
248 decrease of the platelets number ($P < 0.001$) in coinfecting groups ($78.89 \pm 3.51 \times 10^9$ / L) relative
249 to the control groups ($148.22 \pm 13.94 \times 10^9$ /L) as shown by Fig 2. Nevertheless, a non-significant
250 decrease in red blood cells numbers, hematocrit rate the mean blood volume was found in this
251 group.

252

253 **Fig 2 :** Hematological profile of dengue-malaria coinfecting patients (cases) in comparison with
254 dengue monoinfecting patients (controls). *** $P < 0.001$ when compared with the dengue-
255 monoinfecting patients

256

257 Discussion

258 In Cameroon, previous studies showed a silent circulation of dengue in urban areas [26].
259 Moreover, concurrent infections with malaria were sporadically documented [11,18]. However,
260 for the East region which is recognized as an endemic zone for malaria with evidence of Aedes
261 invasion [19,20], no studies on dengue prevalence have been carried out yet. The objective of
262 this study was to contribute to the epidemiological surveillance of this virus which remains
263 understudied in many parts of Cameroon by a compared analysis of the seroprevalence between
264 a dengue mono-infected cohort and dengue-malaria coinfecting group consulting at the HRB.
265 The study was carried out on patient samples collected directly at the HRB.

266 The serological analysis carried out on surveyed subjects revealed a dengue
267 seroprevalence of 14% for malaria subjects against 66.6% in non-malaria patients. This result
268 suggests that the prevalence of dengue is lower in malaria patients than in asymptomatic
269 patients. These findings are consistent with those of Abdul-Ghani et al. who reported a
270 coinfection rate of 4.8% versus a dengue mono-infection seroprevalence of 35.2% in outpatients
271 from Hodeidah city in Yemen [27]. Likewise, Rao et al. found that of 745 dengue-positive cases
272 identified in the Angul of Odisha district in India, only 3% were shown to possess dengue-
273 malaria coinfection [28]. Also, a meta-analysis of 13 studies confirmed reduced odds of co-
274 infected participants as compared to those with dengue mono-infection [29]. However, the
275 coinfection rate found in this study (14%) is close of that of Yousseu et al (13%) reported in
276 Douala (Cameroon) [14], lower than that of Mustapha et al. (44.2%) reported in Abuja (Nigeria)
277 [30] in HIV-patients and higher than that recently documented in febrile patients from the
278 Adamawa region (8.95%) in Cameroon by our research group [18]. Similarly, the dengue
279 mono-infection rate found here is higher than that described by Tchuandom et al (24.8%) in
280 blood donors recruited at the Jamot Hospital in Yaounde [17]. These discrepancies might be
281 explained by the fact that both infections are highly endemic in the East region. Indeed, the
282 eastern region, due to its climatic conditions [24], would be an area more favorable to the
283 circulation of vector insects and therefore of the DENV. Particular attention to climatic factors
284 should be taken into account in future studies to gauge its impact on the prevalence of the virus
285 in this region. In fact, humid months with high rainfall and a temperature above 30°C have been
286 shown to be conducive factors for high malaria-dengue coinfection rate [28]. Also, the high
287 circulation of dengue could be due to the movement of migrants from neighboring endemic
288 areas or the breeding sites proliferation for *Aedes* [30].

289 Considering the limitations associated with the use of rapid diagnostic tests, the
290 underestimation of dengue cases in the present study cannot be ruled out. Other more suitable

291 diagnostic tools with better sensitivity would certainly have made it possible to better refine the
292 diagnosis and even to characterize the viral load of seropositive patients.

293 Regarding the serological analysis of dengue markers, out of the 7 cases of co-infections
294 identified, 42.86% were mainly cases of primary infection due to the unique presence of IgM
295 antibodies while 57.14% % were cases of secondary infection due to concomitant detection of
296 IgG antibodies. This high proportion of IgG could indicate that the virus has been circulating
297 for a long time in Bertoua city. These data are in line with previous studies who reported a high
298 prevalence of malaria and dengue virus IgG in Nigeria[30]. In addition, the proportion of IgM
299 - positive patients could be justified either by the fact that these patients were tested at a moment
300 when the dengue infection was active and IgM antibodies were sufficient enough to be detected
301 or they had been immunized after a recent infection. In the non-malarial population, we
302 recorded 37 cases of patients with primary infection out of the 60 screened (61.66%) with an
303 essentially NS1 type serology, or NS1 and IgM, which in fact reflects an active infection in
304 these patients. The remainder (38.34%) were cases of secondary infection. This result is similar
305 to that reported by Tchandom et al. (2020) who found a seroprevalence of 4.5%, 12.3% and
306 6.1% for the NS1 antigen, IgM, and IgG antibodies respectively [17]. This also suggests that
307 the serological profile is different between the two populations. Considering that most of the
308 patients with secondary infection are found in the case group, it can be hypothesized that these
309 patients were first exposed to dengue before getting malaria.

310 In this study, gender was not statistically associated with dengue infection, although
311 females were found more exposed than male in the two populations. This might be due they
312 were more represented in the study population. These results are consistent with those of a
313 previous cameroonian study that reported an acute dengue seroprevalence of 7.7% in females
314 versus 4.7% in males in children attending health public centers [31]. Likewise, an indian study
315 demonstrated that of 40% of dengue-positive cases identified, women were significantly more

316 exposed than men[32]. However, further studies have shown the contrary. Kumar et al, for
317 example, in a gender-based study in India, reported that men were prominently more affected
318 by dengue infection than women. The socio-cultural background which leads male to more
319 exposed to outdoor activities with less protection for their bodies could have played a role in
320 this exposure [33]. However, as stated by other authors the exact relationship between
321 sociocultural background and gender-specific dengue infection rate should be deeply assessed
322 [34]. Overall, the role of gender as risk factor for dengue infection in malaria and non-malaria
323 patients remains controversial. Further investigations are needed to examine these variations.

324 Among the other demographical factors analyzed, age was statistically associated with
325 dengue infection in both case and control groups with subjects under 16 years of age
326 significantly higher exposed to dengue than older participants (16-30 years) in both populations.
327 These data are in line with previous studies carried out in Cameroon that showed a high
328 susceptibility of infants and children to dengue infection[9,11,14,16,31]. In fact, the quality of
329 environment in which these children live and the applying of protecting measures against
330 mosquitoes, play an important role in the child trend of dengue infection. According to
331 Tchouandom et al. (2019), children who live in houses where water containers are not
332 consistently covered, insecticides not regularly sprayed or those who don't regularly wear long-
333 sleeved shirts have higher prevalence of dengue infection than those applying these measures
334 [31].

335 Regarding places of residence, the Enia Tigaza, Ngaikada, Yademe, Italy and Kano
336 neighborhoods were more associated with dengue infection in coinfecting patients ($P<0.05$)
337 while the Enia, Monou and Kano districts were the only significant sources of contamination
338 for dengue-monoinfected patients. Given that dengue prevalence was higher in monoinfected
339 patients, it could be suggested that Enia, Monou and Kano districts which belong to Bertoua II
340 sub-division are the main disseminating areas for DENV and thus for Aedes propagation. In a

341 geographical study on distribution and prevalence of *Aedes* species through Cameroon, Tedjou
342 et al reported a seroprevalence of 99.1% for *Ae. albopictus* vs 0.9% for *Ae. aegypti* in Bertoua
343 downtown while the vectors were present at 97.97% vs 2.03% rates respectively in Bertoua
344 suburban areas [20].

345 With regard to the haematological parameters, the presence of dengue in the 2
346 populations showed a variation in the haematological parameters. The number of lymphocytes,
347 neutrophils and white blood cells increased in both mono-infected and co-infected compared to
348 normal values, but this increase was not significant between the two groups. The number of red
349 blood cells and the hematocrit level were considerably lower in the co-infected than in the
350 mono-infected with an insignificant variation between the two groups. Likewise, the mean
351 corpuscular volume was slightly lower in co-infected than in mono-infected. However, a
352 significant decrease in the number of platelets was observed in co-infected patients compared
353 to mono-infected patients ($78.89 \pm 3.51 * 10^9 / L$ vs $148.22 \pm 13.94 * 10^9/L$). There may be a
354 few reasons for the thrombocytopenia observed in co-infected such as platelet consumption by
355 activated macrophages during phagocytosis, increased peripheral sequestration, or activation of
356 the complement system as previously stated [35]. On contrary to these data, a meta-analysis
357 study by Kotepui et al. (2019) demonstrated a higher odds of platelets among coinfecting
358 patients relative to dengue-monoinfected patients [29]. Moreover, some studies did not find any
359 significant difference in platelets levels between both groups [36]. However, Barua and Gill in
360 2016 reported a significantly lower platelet value in co-infected patients compared to those uni-
361 infected with dengue (47,587 versus 76,422 / mm³) [37].

362 One of the limitations of this study could be the sample size which, in the future, must be
363 increased to obtain more representative data. Due to resource constraints, it has not been
364 possible to confirm positive IgM by plaque reduction neutralization tests, and serotypes of NS1
365 positive cases. The need to extend sampling throughout the year instead of just 2 months will

366 allow us to better identify the periods at risk of dengue infection in the East region and to
367 analyze the impact of the climate.

368

369 **Conclusion**

370 At the end of this work aiming to analyze the circulation of the dengue virus in malaria patients
371 at the BRH and to compare it with a non-malaria cohort, we can retain that malaria patients
372 have statistically fewer cases of dengue than non-malaria patients. The majority of these cases
373 are dengue secondary infection, whereas in the mono-infected group it is much more of a
374 primary infection. In addition, in the two populations, gender was not statistically associated
375 with seropositivity to dengue, but age and the fact of living in certain neighborhoods of the city
376 of Bertoua would statistically increase the chances of being exposed to dengue. Regarding
377 haematological parameters, we noted that the decrease in blood platelets is the flagship
378 hematological modification that can lead a malaria patient to be suspected of a case of dengue,
379 even though alterations in white blood cells, red blood cells and hematocrit can be noted. The
380 results of this study point the endemic character of dengue infection in East-Cameroon. Further
381 investigations are necessary to characterize the circulating serotypes and even follow up
382 patients with mono- or co-infection for complications .

383 **Acknowledgments**

384 We express our sincere thanks to all the volunteers who participated to this study. Also, the
385 technical assistance of the personal from the Laboratory of the BRH is greatly acknowledged.
386 The study was partly possible thanks to an research grant (F/6125-1) from International
387 Foundation for Science, which helped us to acquire Dengue kits. The funders had no role in
388 study design, data collection and analysis, decision to publish, or preparation of the manuscript

389 Declaration of Interests

390 The authors of this manuscript have no competing interests to disclose.

391 Bibliography

- 392 1. Libraty DH. Viral Febrile Illnesses. Hunter's Tropical Medicine and Emerging
393 Infectious Disease: Ninth Edition. W.B. Saunders; 2013. pp. 306–322.
394 doi:10.1016/B978-1-4160-4390-4.00184-3
- 395 2. WHO. Dengue and severe dengue. In: WHO [Internet]. 21 May 2021 [cited 21 Aug
396 2021] p. 1. Available: [https://www.who.int/news-room/fact-sheets/detail/dengue-and-](https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue)
397 [severe-dengue](https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue)
- 398 3. Messina J, Brady O, Golding N, Kraemer M, Wint G, Ray S, et al. The current and future
399 global distribution and population at risk of dengue. *Nat Microbiol.* 2019;4: 1508–1515.
400 doi:10.1038/S41564-019-0476-8
- 401 4. Eltom K, Enan K, El Hussein A, Elkhidir I. Dengue Virus Infection in Sub-Saharan
402 Africa Between 2010 and 2020: A Systematic Review and Meta-Analysis. *Front Cell*
403 *Infect Microbiol.* 2021;11: 1–12. doi:10.3389/FCIMB.2021.678945
- 404 5. Simo F, Bigna J, Kenmoe S, Ndangang M, Temfack E, Moundipa P, et al. Dengue virus
405 infection in people residing in Africa: a systematic review and meta-analysis of
406 prevalence studies. *Sci Rep.* 2019;9. doi:10.1038/S41598-019-50135-X
- 407 6. Maze MJ, Bassat Q, Feasey NA, Mandomando I, Musicha P, Crump JA. The
408 epidemiology of febrile illness in sub-Saharan Africa: implications for diagnosis and
409 management. *Clin Microbiol Infect.* 2018;24: 808. doi:10.1016/J.CMI.2018.02.011
- 410 7. Guzman MG, Harris E. Dengue. *Lancet.* 2015;385: 453–465. doi:10.1016/S0140-
411 6736(14)60572-9
- 412 8. Grunnill M, Boots M. How Important is Vertical Transmission of Dengue Viruses by
413 Mosquitoes (Diptera: Culicidae)? *J Med Entomol.* 2016;53: 1–19.
414 doi:10.1093/JME/TJV168
- 415 9. Tchetsna HS, Yousseu FS, Kamgang B, Tedjou A, McCall PJ, Wondji C. Concurrent
416 circulation of dengue serotype 1, 2 and 3 among acute febrile patients in Cameroon.
417 medRxiv. 2021; 2021.05.10.21256254. Available:
418 [https://www.medrxiv.org/content/10.1101/2021.05.10.21256254v1%0Ahttps://www.m](https://www.medrxiv.org/content/10.1101/2021.05.10.21256254v1%0Ahttps://www.medrxiv.org/content/10.1101/2021.05.10.21256254v1.abstract)
419 [edrxiv.org/content/10.1101/2021.05.10.21256254v1.abstract](https://www.medrxiv.org/content/10.1101/2021.05.10.21256254v1.abstract)
- 420 10. Nkenfou CN, Fainguem N, Dongmo-Nguefack F, Yatchou LG, Kameni JJK, Elong EL,
421 et al. Enhanced passive surveillance dengue infection among febrile children:
422 Prevalence, co-infections and associated factors in Cameroon. *PLoS Negl Trop Dis.*
423 2021;15: 1–10. doi:10.1371/journal.pntd.0009316
- 424 11. Mouiche MMM, Ntumvi NF, Maptue VT, Tamoufe U, Albert B, Ngum Ndze V, et al.
425 Evidence of Low-Level Dengue Virus Circulation in the South Region of Cameroon in
426 2018. *Vector-Borne Zoonotic Dis.* 2020;20: 1–4. doi:10.1089/vbz.2019.2531

- 427 12. Tchuandom SB, Lissom A, Ateba GHM, Tchouangueu TF, Tchakounte C, Ayuk AR, et
428 al. Dengue virus serological markers among potential blood donors: An evidence of
429 asymptomatic dengue virus transmission in cameroon. *Pan Afr Med J.* 2020;36.
430 doi:10.11604/pamj.2020.36.185.22128
- 431 13. Tchuandom SB, Tchadji JC, Tchouangueu TF, Biloa MZ, Atabonkeng EP, Fumba MIM,
432 et al. A cross-sectional study of acute dengue infection in paediatric clinics in Cameroon.
433 *BMC Public Health.* 2019;19. doi:10.1186/s12889-019-7252-9
- 434 14. Yousseu FBS, Neng FBS, Ngouanet SA, Mekanda FMO, Demanou M. Detection and
435 serotyping of dengue viruses in febrile patients consulting at the New-Bell District
436 Hospital in Douala, Cameroon. *PLoS One.* 2018;13: e0204143.
437 doi:10.1371/journal.pone.0204143
- 438 15. Monamele GC, Demanou M. First documented evidence of dengue and malaria co-
439 infection in children attending two health centers in yaoundé, cameroon. *Pan Afr Med J.*
440 2018;29: 227. doi:10.11604/pamj.2018.29.227.15316
- 441 16. Tchuandom SB, Tchouangueu TF, Antonio-Nkondjio C, Lissom A, Djang JON,
442 Atabonkeng EP, et al. Seroprevalence of dengue virus among children presenting with
443 febrile illness in some public health facilities in Cameroon. *Pan Afr Med J.* 2018;31: 177.
444 doi:10.11604/pamj.2018.31.177.16390
- 445 17. Tchuandom SB, Lissom A, Ateba GHM, Tchouangueu TF, Tchakounte C, Ayuk AR, et
446 al. Dengue virus serological markers among potential blood donors: an evidence of
447 asymptomatic dengue virus transmission in Cameroon. *Pan Afr Med J.* 2020;36: 1–11.
448 doi:10.11604/PAMJ.2020.36.185.22128
- 449 18. Galani TBR, Mapouokam DW, Neng Simo FB, Mohamadou H, Djamien Chuisseu PD,
450 Njintang NY, et al. Investigation of Dengue-Malaria co-infection among febrile patients
451 consulting at Ngaoundere Regional Hospital, Cameroon. *J Med Virol.* 2021;93: 3350–
452 3361. doi:10.1002/jmv.26732
- 453 19. Kamgang B, Marcombe S, Chandre F, Nchoutpouen E, Nwane P, Etang J, et al.
454 Insecticide susceptibility of *Aedes aegypti* and *Aedes albopictus* in Central Africa.
455 *Parasit Vectors.* 2011;4: 79. doi:10.1186/1756-3305-4-79
- 456 20. Tedjou AN, Kamgang B, Yougang AP, Njiokou F, Wondji CS. Update on the
457 geographical distribution and prevalence of *Aedes aegypti* and *Aedes albopictus*
458 (Diptera: Culicidae), two major arbovirus vectors in Cameroon. *PLoS Negl Trop Dis.*
459 2019;13: e0007137. doi:10.1371/JOURNAL.PNTD.0007137
- 460 21. Chiabi A, Tchokoteu PF, Toupouri A, Mbeng TB, Wefuan J. The clinical spectrum of
461 severe malaria in children in the east provincial hospital of Bertoua, Cameroon. *Bull la*
462 *Soc Pathol Exot.* 2004;97: 239–243.
- 463 22. Antonio-Nkondjio C, Ndo C, Njiokou F, Bigoga JD, Awono-Ambene P, Etang J, et al.
464 Review of malaria situation in Cameroon: technical viewpoint on challenges and
465 prospects for disease elimination. *Parasit Vectors.* 2019;12: 501. doi:10.1186/S13071-
466 019-3753-8
- 467 23. PopulationData. Cameroun • Fiche pays • In: PopulationData.net [Internet]. 2020 [cited
468 22 Aug 2021] p. 1. Available: <https://www.populationdata.net/pays/cameroun/>
- 469 24. Pello G. Migration transfrontalière et droits économiques et sociaux - Irénées. In:

- 470 Irrenees [Internet]. 2015 [cited 21 Aug 2021] p. 1. Available:
471 http://www.irenees.net/bdf_fiche-analyse-1088_fir.html?imprimer=1
- 472 25. Adusei KA, Owusu-Ofori A. Protocols for preparation of blood smears, reporting of
473 malaria parasites, processing of blood samples using malaria RDT (HRP-2), blood
474 grouping and design of questionnaire. *Protocols.io*. 2018; 1–4.
475 doi:10.17504/PROTOCOLS.IO.PRYDM7W
- 476 26. Fokam EB, Levai LD, Guzman H, Amelia PA, Titanji VPK, Tesh RB, et al. Silent
477 circulation of arboviruses in Cameroon. *East Afr Med J*. 2010;87: 262–268.
478 doi:10.4314/EAMJ.V87I6.63085
- 479 27. Abdul-Ghani R, Mahdy MAK, Alkubati S, Al-Mikhlafy AA, Alhariri A, Das M, et al.
480 Malaria and dengue in Hodeidah city, Yemen: High proportion of febrile outpatients
481 with dengue or malaria, but low proportion co-infected. *PLoS One*. 2021;16: e0253556.
482 doi:10.1371/JOURNAL.PONE.0253556
- 483 28. Rao MRK, Padhy RN, Das MK. Prevalence of dengue viral and malaria parasitic co-
484 infections in an epidemic district, Angul of Odisha, India: An eco-epidemiological and
485 cross-sectional study for the prospective aspects of public health. *J Infect Public Health*.
486 2016;9: 421–428. doi:10.1016/J.JIPH.2015.10.019
- 487 29. Kotepui M, Kotepui KU. Prevalence and laboratory analysis of malaria and dengue co-
488 infection: a systematic review and meta-analysis. *BMC Public Heal* 2019 191. 2019;19:
489 1–12. doi:10.1186/S12889-019-7488-4
- 490 30. Mustapha JO, Emeribe AU, Nasir IA. Survey of malaria and anti-dengue virus IgG
491 among febrile HIV-infected patients attending a tertiary hospital in Abuja, Nigeria.
492 *HIV/AIDS - Res Palliat Care*. 2017;9: 145–151. doi:10.2147/HIV.S134023
- 493 31. Tchuandom SB, Tchadji JC, Tchouangueu TF, Biloa MZ, Atabonkeng EP, Fumba MIM,
494 et al. A cross-sectional study of acute dengue infection in paediatric clinics in Cameroon.
495 *BMC Public Heal* 2019. 2019;19: 1–7. doi:10.1186/S12889-019-7252-9
- 496 32. Chakravarti A, Arora R, Luxemburger C. Fifty years of dengue in India. *Trans R Soc*
497 *Trop Med Hyg*. 2012;106: 273–282.
- 498 33. Kumar M, Verma K, Mishra B. Prevalence of Dengue Fever in Western Uttar Pradesh,
499 India: A Gender-Based Study. *Int J Appl Basic Med Res*. 2020;10: 8–11.
500 doi:10.4103/ijabmr.IJABMR
- 501 34. Joob B, Wiwanitkit V. Gender and Prevalence of Dengue Fever. *Int J Appl Basic Med*
502 *Res*. 2020;10: 295. doi:10.4103/IJABMR.IJABMR_9_20
- 503 35. De Azeredo EL, Monteiro RQ, De-Oliveira Pinto LM. Thrombocytopenia in dengue:
504 Interrelationship between virus and the imbalance between coagulation and fibrinolysis
505 and inflammatory mediators. *Mediators Inflamm*. 2015;2015: 1–16.
506 doi:10.1155/2015/313842
- 507 36. Magalhaes BM., Siqueira A., Alexandre MA., Souza M., Gimaque J., Bastos M., et al.
508 *P. vivax* Malaria and Dengue Fever Co-infection: A Cross-Sectional Study in the
509 Brazilian Amazon. *PLoS Negl Trop Dis*. 2014;8: e3239.
- 510 37. Barua A, Gill N. A comparative study of concurrent dengue and malaria infection with
511 their mono-infection in a teaching hospital in Mumbai. *J Assoc Physicians India*. 2016;64:
512 49–52.

513

514





Fig 1

